Fake drug probe: Karnataka FDA demands Pfizer’s 'immediate intervention'

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

Florida sued Pfizer and CEO Albert Bourla, alleging the company misled consumers about COVID-19 vaccine safety and effectiveness, and employed unfair market tactics. The state seeks fines and a court order to halt the alleged conduct. Pfizer denies the claims, stating its statements were accurate and based on science. According to the lawsuit, Pfizer made over $80 billion from vaccine sales, raising prices from $30 to $110-$130 per dose by 2023.

Florida Attorney General James Uthmeier sued Pfizer and its CEO, alleging the company misled the public about the safety of its COVID-19 vaccine. The lawsuit was filed on October 1 in St. Lucie County. According to the complaint, Pfizer's statements were misleading, impacting public trust in the vaccine. The case is ongoing, and Pfizer has not yet publicly responded to the allegations.

Pfizer Inc. reported positive results from two Phase 3 trials of LITFULO (ritlecitinib) for nonsegmental vitiligo. The trials showed significant improvements in facial and total body repigmentation compared to placebo. Pfizer plans to submit these data to global regulatory authorities, including the FDA and EMA. LITFULO is already approved for severe alopecia areata.

Pfizer sued Sun Pharmaceutical in federal court, alleging its generic versions of lung cancer drug Lorbrena infringe four patents. The patents expire between 2033 and 2038. Lorbrena had $407M in US sales in 2025, per Bloomberg. Pfizer seeks to block Sun's copies and unspecified damages.

Pfizer (PFE) reported positive Phase 3 trial results for LITFULO, a vitiligo treatment, showing significant skin repigmentation. The company plans regulatory submissions. PFE has a 6.35% dividend yield, a payout ratio of 0.71, and a GF Score of 71/100, indicating fair valuation but modest growth.